CND Life Sciences

CND Life Sciences, founded in 2017, is dedicated to supporting patients with neurodegenerative and other related diseases. Operating a CLIA-certified laboratory in Phoenix, Arizona, CND launched the Syn-One Test™, the world’s first commercial test capable of detecting, visualizing, and quantifying the presence of abnormally phosphorylated α-synuclein in skin nerve fibers. This test is designed as an objective, evidence-based diagnostic tool to help confirm synucleinopathies in patients suspected of having Parkinson’s disease (PD), dementia with Lewy bodies (DLB), multiple system atrophy (MSA), pure autonomic failure (PAF), or REM sleep behavior disorder (RBD). Through proprietary staining and analysis of three small punch skin biopsies provided by clinicians, CND offers a convenient, accurate, and minimally invasive option to enhance clarity and confidence in diagnosing neurodegenerative diseases.